AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Generate Biomedicines, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00X9D0P03
12.41▼ 0.38 (-2.97%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
12.79
Day's Range
12.20 – 12.94
52-Week Range
11.00 – 22.67
Volume
295.6K
Avg Volume
1.1M
Share Statistics
Shares Outstanding
Employees
—
Exchange
XNAS
Listed
2026-02-27
Share count as of July 29, 2026

Generate Biomedicines, Inc. Common Stock (GENB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Generate Biomedicines, Inc. Common Stock (GENB)
What is Generate Biomedicines, Inc. Common Stock's Market Cap?
Generate Biomedicines, Inc. Common Stock's Market Cap is $1.6B, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · GENBAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue1234.2%987.5%
Loss from operations
% of revenue-1134.2%-887.5%
Other income (expense), net
Change in fair value of convertible preferred stock warrant liability
Interest expense
Interest income
Foreign currency exchange loss
Total other income (expense), net
Loss before provision for income taxes
Provision for income taxes
Net loss
% of revenue-1065.2%-854.3%
Net loss attributable to non-controlling interests
Net loss attributable to Generate Biomedicines, Inc. stockholders
% of revenue-1065.2%-850.6%
Net loss attributable to Generate Biomedicines, Inc. common stockholders
Net loss per share, basic
Net loss per share, diluted